LAG3 antibody (C-Term)

Catalog No. ABIN6745431

This anti-LAG3 antibody is a Rabbit Polyclonal antibody detecting LAG3 in WB. Suitable for Human, Mouse, Rat, Cow and Drosophila melanogaster.

Quick Overview for LAG3 antibody (C-Term) (ABIN6745431)

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Reactivity: Human, Mouse, Rat, Cow, Drosophila melanogaster

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LAG3 antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-LAG3 Antibody

Binding Specificity: C-Term

Specificity: Human LAG3 / LAG-3

Predicted Reactivity: Percent identity by BLAST analysis: Human (100%).

Purification: Immunoaffinity purified

Immunogen: Synthetic peptide from C-Terminus of human LAG3 (P18627, NP_002277). Percent identity by BLAST analysis: Human, Gorilla, Mouse, Rat, Bovine, Lizard, Seabass, Drosophila (100%).

Type of Immunogen: Synthetic peptide

Application Details

Application Notes: Approved: WB (0.2 - 1 μg/mL)

Usage: Western Blot: Suggested dilution at 1 μg/mL in 5 % skim milk / PBS buffer, and HRP conjugated anti-Rabbit IgG should be diluted in 1: 50,000 - 100,000 as secondary antibody.

Comment:

Target Species of Antibody: Human

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Distilled water

Concentration: Lot specific

Buffer: Lyophilized from PBS with 2 % sucrose

Handling Advice: Avoid repeat freeze-thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment: Long term: -20°C, the use of 50% glycerol is recommended if storing aliquots in -20°C for long term use (up to 1 year)
Short term (less than 1 week): 4°C. Avoid freeze-thaw cycles.

Target Details for LAG3

Target: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Alternative Name: LAG3 / LAG-3 / CD223

Background: Name/Gene ID: LAG3

Synonyms: LAG3, CD223 antigen, LAG-3, Protein FDC, CD223, FDC, Lymphocyte-activation gene 3

Gene ID: 3902

NCBI Accession: NP_002277

UniProt: P18627

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints